Adaptive Biotechnologies Corp
NASDAQ:ADPT
Balance Sheet
Balance Sheet Decomposition
Adaptive Biotechnologies Corp
Current Assets | 410.2m |
Cash & Short-Term Investments | 346.4m |
Receivables | 38m |
Other Current Assets | 25.8m |
Non-Current Assets | 250.9m |
PP&E | 120.3m |
Intangibles | 124.1m |
Other Non-Current Assets | 6.5m |
Current Liabilities | 88m |
Accounts Payable | 7.7m |
Accrued Liabilities | 31.7m |
Other Current Liabilities | 48.6m |
Non-Current Liabilities | 264.7m |
Other Non-Current Liabilities | 264.7m |
Balance Sheet
Adaptive Biotechnologies Corp
Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash & Cash Equivalents |
85
|
55
|
97
|
123
|
139
|
90
|
65
|
|
Cash Equivalents |
85
|
55
|
97
|
123
|
139
|
90
|
65
|
|
Short-Term Investments |
107
|
110
|
480
|
565
|
214
|
408
|
281
|
|
Total Receivables |
6
|
5
|
13
|
10
|
17
|
40
|
38
|
|
Accounts Receivables |
6
|
5
|
13
|
10
|
17
|
40
|
38
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
5
|
8
|
9
|
14
|
19
|
15
|
14
|
|
Other Current Assets |
3
|
3
|
14
|
15
|
13
|
9
|
11
|
|
Total Current Assets |
205
|
181
|
613
|
727
|
403
|
562
|
410
|
|
PP&E Net |
14
|
19
|
60
|
139
|
173
|
164
|
120
|
|
PP&E Gross |
14
|
19
|
60
|
139
|
173
|
164
|
120
|
|
Accumulated Depreciation |
9
|
13
|
18
|
24
|
36
|
54
|
73
|
|
Intangible Assets |
15
|
14
|
12
|
10
|
9
|
7
|
5
|
|
Goodwill |
119
|
119
|
119
|
119
|
119
|
119
|
119
|
|
Long-Term Investments |
9
|
0
|
105
|
119
|
217
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
3
|
3
|
3
|
5
|
7
|
|
Other Assets |
119
|
119
|
119
|
119
|
119
|
119
|
119
|
|
Total Assets |
363
N/A
|
333
-8%
|
912
+174%
|
1 116
+22%
|
923
-17%
|
857
-7%
|
661
-23%
|
|
Liabilities | ||||||||
Accounts Payable |
2
|
2
|
5
|
3
|
3
|
8
|
8
|
|
Accrued Liabilities |
4
|
7
|
10
|
27
|
30
|
37
|
32
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
15
|
14
|
63
|
75
|
81
|
64
|
49
|
|
Total Current Liabilities |
21
|
23
|
78
|
105
|
114
|
110
|
88
|
|
Long-Term Debt |
0
|
0
|
37
|
0
|
0
|
0
|
0
|
|
Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
4
|
7
|
226
|
268
|
205
|
283
|
265
|
|
Total Liabilities |
26
N/A
|
30
+16%
|
341
+1 041%
|
373
+9%
|
319
-14%
|
393
+23%
|
353
-10%
|
|
Equity | ||||||||
Common Stock |
561
|
561
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
249
|
296
|
366
|
512
|
719
|
919
|
1 144
|
|
Additional Paid In Capital |
25
|
38
|
936
|
1 254
|
1 324
|
1 387
|
1 453
|
|
Other Equity |
0
|
0
|
1
|
1
|
1
|
4
|
0
|
|
Total Equity |
337
N/A
|
303
-10%
|
571
+89%
|
743
+30%
|
604
-19%
|
464
-23%
|
308
-34%
|
|
Total Liabilities & Equity |
363
N/A
|
333
-8%
|
912
+174%
|
1 116
+22%
|
923
-17%
|
857
-7%
|
661
-23%
|
|
Shares Outstanding | ||||||||
Common Shares Outstanding |
119
|
119
|
125
|
138
|
141
|
143
|
145
|